Astellas Gene Therapies (Astellas Gene) is a biotechnology company that focuses on the development and commercialization of gene therapy products for rare diseases. The company’s major pipeline products include AT132, AT845, ASP2016, AT466 and KT430. It's products are used for the treatment of X-linked myotubular myopathy, pompe disease, muscular dystrophy in children and neuromuscular disease, severe respiratory insufficiency, weakness and hypotonia. The company is currently exploring three gene therapy modalities such as gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. Astellas Gene is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
480 Forbes Boulevard, San Francisco, California, 94080
Website
www.astellasgenetherapies.com
Industry
Pharmaceuticals and Healthcare
Astellas Gene Therapies premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AT132 - X-linked Myotubular Myopathy |
| AT845 - Pompe Disease |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Astellas Gene Therapies | Amicus Therapeutics Inc | Nektar Therapeutics | Capsida Biotherapeutics Inc | Dimension Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | Philadelphia | San Francisco | Thousand Oaks | Cambridge |
| State/Province | California | Pennsylvania | California | California | Massachusetts |
| No. of Employees | - | 517 | 137 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Morten Sogaard | President; Head - Division | Senior Management | - | - |
| Amy Pott | Senior Vice President - Commerical | Senior Management | - | - |
| Carolyn Sasse | Head - Cell and Gene Therapy Development; Vice President | Senior Management | - | - |
| Don Mather | Senior Vice President - BioPharma Manufacturing | Senior Management | - | - |
| David Smethurst | Vice President; Head - Regulatory Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward